1. Home /
    2. Altai Protocol Library /
  2. New Reference: Trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Reference: Trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer

New Reference: Trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
Study:
  • Phase III, randomized, controlled, multicenter, open-label trial (DESTINY-Breast-02)
  • HER2-positive, previously received trastuzumab-emtansine, unresectable or metastatic breast cancer
  • Trastuzumab-deruxtecan (n=406) vs. SOC (n=202)
Efficacy:
  • mPFS: 17.8 vs 6.9 mos, p<0.0001
  • 12 months PFS: 62% vs. 27%
  • 24 months PFS: 42% vs 13%
  • mOS: 39.2 vs. 26.5 mos, p=0021
  • 12 months OS: 89.4% vs.74.7%
  • 24 months OS: 65.9% vs.54.3%
Safety:
  • Grade≥3 AEs: Neutropenia (11% vs 2%), Anemia (8% vs. 3%), nausea (7% vs 3%), palmar-plantar erythrodysesthesia (1% vs 10%), diarrhea (3% vs. 7%)

Lancet Oncol, 20 APR, 2023

Andre F et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomized, open-label, multicentre, phase 3 trial,

http://doi.org/10.1016/S0140-6736(23)00725-0

Reviewed by Elvin CHALABİYEV, MD on MAY 10, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More